Cancer52 is delighted to announce that Clara Mackay, Deputy CEO of Pancreatic Cancer UK, has been appointed as interim chair of Cancer52.
She has a great understanding of the issues that affect rare and less common cancers, as pancreatic cancer has one of the poorest cancer survival statistics of all cancers.
Said the Cancer52 board "We are pleased to confirm the appointment of Clara Mackay as interim Chair – we are sure she will bring the qualities her position with Pancreatic Cancer UK utilises so well to her new role with Cancer52.”
Clara's appointment takes effect immediately.